Eva Holtved

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

Ken Kato, Byoung Chul Cho, Masanobu Takahashi et al. · The Lancet Oncology · 2019 · 1.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

Yuichiro� Doki, Jaffer A. Ajani, Ken Kato et al. · UCL Discovery (University College London) · 2022 · 532 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.

Ian Chau, Yuichiro� Doki, Jaffer A. Ajani et al. · Journal of Clinical Oncology · 2021 · 111 citations

Medicine, Oncology, Pharmacology +17

Delineation of whole heart and substructures in thoracic radiation therapy: National guidelines and contouring atlas by the Danish Multidisciplinary Cancer Groups

Marie Louise Holm Milo, Birgitte Vrou Offersen, Troels Bechmann et al. · Radiotherapy and Oncology · 2020 · 81 citations

Medicine, Oncology, Radiation Oncology +17

Evaluation of miR-21 and miR-375 as prognostic biomarkers in esophageal cancer

Mette Winther, Jan Alsner, Trine Tramm et al. · Acta Oncologica · 2015 · 51 citations · Full text

Medicine, Cancer Biology, Oncology +17